Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases

Hirofumi Ichida,
Yoshihiro Mise,
Hiromichi Ito,
Takeaki Ishizawa,
Yosuke Inoue,
Yu Takahashi,
Eiji Shinozaki,
Kensei Yamaguchi and
Akio SaiuraEmail author

World Journal of Surgical Oncology201917:100

https://doi.org/10.1186/s12957-019-1641-5

Received: 2 April 2019
Accepted: 3 June 2019
Published: 13 June 2019

Abstract

Background

There are no optimal indication criteria for neoadjuvant chemotherapy (NAC) in patients with resectable colorectal liver metastases (CLM). The aim of this study was to prospectively assess the survival benefit of selective NAC administration in this patient population based on tumor characteristics.

Methods

Borderline resectable CLM (BR-CLM) were defined as four or more liver metastases, CLM larger than 5 cm, or CLM with concomitant resectable extrahepatic metastases. From 2010 to 2015, NAC was administered to BR-CLM patients. Upfront surgery without NAC was performed to patients having clearly resectable CLM (less than 3 lesions, smaller than 5 cm, and no extrahepatic metastases: CR-US group). Survival outcomes of the two groups were assessed.

Results

The BR-NAC group comprised 73 patients and the CR-US group 172. All patients in the BR-NAC group underwent subsequent resection, as none showed disease progression or chemotherapy-associated liver damage. The 3- and 5-year overall survival rates of the CR-US group were 83.0% and 74.0%, while patients in the BR-NAC group had comparable 3-year and 5-year overall survivals (80.5% and 66.6%, P = 0.397).

Conclusion

Defining BR-CLM based on tumor characteristics optimizes patient selection for NAC. Favorable overall survival can be achieved by upfront surgery in patients with clearly resectable CLM and by NAC in patients with BR-CLM.